Genova Diagnostics launched its new Alzheimer’s Assessment solution, which is a non-invasive blood test utilizing the p-Tau217 biomarker for early detection of Alzheimer’s disease. This initiative is enabled by a strategic partnership with Neurocode, a provider in neurological diagnostics and research.
Alzheimer’s Assessment Test
The new Alzheimer’s Assessment is designed to serve as a significant advancement in the early detection of Alzheimer’s disease. By leveraging the p-Tau217 biomarker, this blood test provides highly accurate results that can identify Alzheimer’s disease years before clinical symptoms appear, allowing for early intervention and management of the disease, the companies say. The test offers a less invasive alternative to traditional cerebrospinal fluid and imaging tests, making it an accessible and convenient tool in the fight against Alzheimer’s.
“Our partnership with Neurocode has enabled us to bring this state-of-the-art Alzheimer’s Assessment to the market,” says Jeff Ledford, CEO of Genova Diagnostics. “By combining our expertise in laboratory services with Neurocode’s cutting-edge neurological research, we can offer a test that significantly impacts the early diagnosis and treatment of Alzheimer’s disease. This is a significant step forward in our mission to provide innovative, science-based diagnostic services that improve patient outcomes.”
Genova Diagnostics and Neurocode Collaboration
Genova Diagnostics provides healthcare practitioners and individuals with the tools they need to make informed decisions about their health, according to the organizations. The collaboration with Neurocode exemplifies Genova’s commitment to advancing medical research and expanding its portfolio of diagnostic solutions.
“Neurocode is honored to work with Genova in the clinical launch of Alzpath pTau217 assay for accurately detecting amyloid pathology of Alzheimer’s type,” says Hans Frykman, Chief Science Officer of Neurocode. “Neurocode has performed the most extensive clinical validation in the industry, making our test very trustworthy even for people with very minor memory issues.”
The Alzheimer’s Assessment is available now to healthcare providers. Results include personalized assessments and clinical context for patient care.
“Offering the pTau217 biomarker through partnership with Genova Diagnostics gives drastic accessibility to a larger segment of people that can now monitor amyloid activity in their brains with a simple blood draw,” says Roopa Reddy, CEO at Neurocode. “Neurocode is very excited to realize this potential.”
